systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation

Intravitreal injections of ranibizumab [IVR] and bevacizumab [IVB] have both been used as treatments for myopic choroidal neovascularisation. We aimed to produce a meta-analysis of published literature comparing IVR with IVB for the treatment of myopic choroidal neovascularisation, by searching electronic databases from January 1950 to March 2013. Our search produced three suitable studies that reported on 117 patients in total. The results of the meta-analysis demonstrated that the mean number of lines improvement after IVR appeared better compared with IVB [fixed effects model: SMD = 0.46, 95% CI [0.09, 0.83], z = 2.44, p = 0.01]. The number of patients who had a greater than 3 line improvement was similar between groups [fixed effects model: RR = 0.95, 95% CI [0.67, 1.32], z = 0.33, p = 0.74]. At follow up there was no difference in number of those who had an absence of leakage [fixed effects model: RR = 1.04, 95% CI [0.93, 1.16], z = 0.64, p = 0.52]. There was no statistical significance between the two groups in relation to the number of injections [random effects model: SMD = -0.25, 95% CI [-1.12, 0.61], z = 0.57, p = 0.57]. Early evidence therefore suggests that intravitreal injections of ranibizumab are comparable to intravitreal injections of bevacizumab in the treatment of myopic choroidal neovascularisation. Both treatments result in a statistically significant increase in visual acuity with high numbers of patients maintaining stable vision. Further studies are still needed to strengthen results

pathophysiologic classification of blood disorders

In these classifications of haemopoietic diseases, we tried at the same time to integrate them together. This was done by dividing them first into disorders of haemopoiesis and of haemostasia. We integrated together the different cellular disorders under the heading of haemocytopenia, haeroocytosis and hoemocythemias. The unity of these disorders, the use of one single classification for the different causes of decrease of the erythrocytes, leucocytes and thrombocytes facilitates the approach to the disorders and stress their correlation. Also, the use of one single classification for the causes of increase of the erythrocytes and thrombocytes serves the same aim. The classification given to proliferative diseases group together disorders as the leukaemias, lymphomas and reticulosis which seemed previously not related. Grouping together the manifestations of the different disorders of haemopoiesis obviate their unity and facilitate their description and memorization. The same goes for the manifestations of the haemorrhagic disorders. Such an approach makes the understanding and the diagnosis of the haemopoietic diseases easier